Drug intelligence / Profile preview

doxorubicin + prochlorperazine

Development stage: Unknown
Lead developer: ForDoz Pharma
Modality: Small Molecules
Administration: Intravenous

Overview

A combination therapy where prochlorperazine is used as a doxorubicin-efflux blocker to enhance doxorubicin retention in drug-resistant cancer cells. Doxorubicin is a cytotoxic anthracycline antibiotic that works primarily through DNA intercalation, leading to DNA damage and generation of reactive oxygen species. Prochlorperazine, a phenothiazine derivative, blocks the efflux of doxorubicin from cancer cells, potentially overcoming drug resistance mechanisms. This combination aims to improve doxorubicin retention in tumor cells while potentially reducing normal tissue toxicity.

Targets

DRD2 (Dopamine D2 Receptor)ABCB1 (P-glycoprotein)DNA

Beyond the preview

Go deeper on doxorubicin + prochlorperazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxorubicin + prochlorperazine.

Explore the full profile